Respiratory symptoms are key drivers for starting Kaftrio (elexacaftor/tezacaftor/ivacaftor) among adults with cystic fibrosis (CF) who have stable, near-normal breathing ability, known as preserved lung function, a survey study in Europe has found. In surveying CF centers across the continent, the research team found that clinicians were more likely…